 - Patients who are receiving treatment with medications that are known to be strong inducers or inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 45 CYP3A45 and CYP3A45 substrates with QT prolongation risk that cannot be discontinued prior to study entry 